Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Duncan
CANT
Charles Duncan
Wall Street Analyst
★☆☆☆☆
#2437
on 13Foresight · ranked by our own returns
53%
Success Rate
+13.8%
Average Return
27 of 51 calls profitable · -5.2% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 53% of Charles Duncan's ratings turned a profit when each position was held for 1 year — averaging +13.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

4 Buy 0 Hold 0 Sell
Charles's Stock Coverage 55 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
HRMY
Harmony Biosciences Holdings
Sep 24, 2025 BUY Strong Buy
+39.5% avg upside
13 analysts
$50.00
50.29% Upside
+12.4%
SLDB
Solid Biosciences
Sep 22, 2025 BUY Strong Buy
+92.3% avg upside
23 analysts
$16.00
92.14% Upside
+33.9%
XENE
Xenon
May 13, 2025 BUY Strong Buy
+19.0% avg upside
28 analysts
$55.00
3.95% Upside
+88.8%
ALKS
Alkermes
May 11, 2025 BUY Strong Buy
-17.5% avg upside
34 analysts
$43.00
4.32% Downside
+13.4%
ACAD
ACADIA Pharmaceuticals
Feb 27, 2025 BUY Strong Buy
+66.0% avg upside
42 analysts
$28.00
29.44% Upside
+27.0%
JAZZ
Jazz Pharmaceuticals
Feb 26, 2025 HOLD Strong Buy
-1.8% avg upside
35 analysts
$150.00
33.19% Downside
+31.1%
AXSM
Axsome Therapeutics
Feb 18, 2025 BUY Strong Buy
-10.6% avg upside
28 analysts
$153.00
38.96% Downside
+44.2%
VNDA
Vanda
Feb 14, 2025 BUY Strong Buy
+253.1% avg upside
13 analysts
$13.00
124.20% Upside
+37.8%
GHRS
GH Research
Feb 13, 2025 BUY Strong Buy
+64.5% avg upside
11 analysts
$14.00
37.06% Downside
+2.7%
DRUG
Bright Minds Biosciences
Jan 10, 2025 BUY Strong Buy
+120.9% avg upside
10 analysts
+123.1%
PRTA
Prothena
Sep 30, 2024 BUY Buy
+160.9% avg upside
14 analysts
-41.7%
VXRT
Vaxart
Aug 30, 2024 HOLD Strong Buy
+1311.1% avg upside
8 analysts
-55.2%
CGTX
Cognition Therapeutics
Aug 30, 2024 HOLD Strong Buy
+305.1% avg upside
9 analysts
+400.0%
BIVI
BioVie
Jun 21, 2024 HOLD Buy
+847.0% avg upside
6 analysts
-78.1%
CPRX
Catalyst Pharma
Mar 01, 2024 BUY Strong Buy
-17.0% avg upside
15 analysts
$34.00
8.39% Upside
+34.6%
CYTK
Cytokinetics
Dec 27, 2023 BUY Strong Buy
+8.9% avg upside
36 analysts
$101.00
28.12% Upside
-43.2%
SEELQ
Seelos Therapeutics
Sep 20, 2023 HOLD Buy
+46385614.3% avg upside
10 analysts
-99.7%
CRNX
Crinetics Pharmaceuticals
Sep 11, 2023 BUY Strong Buy
+121.2% avg upside
20 analysts
$52.00
44.87% Upside
+94.6%
DNLI
Denali Therapeutics
Aug 30, 2023 BUY Strong Buy
+60.2% avg upside
24 analysts
$85.00
264.60% Upside
+4.8%
HELP
Helus Pharma
Aug 28, 2023 BUY Strong Buy
+861.2% avg upside
12 analysts
$3.00
35.80% Downside
·
CMPS
COMPASS Pathways
Aug 16, 2023 BUY Strong Buy
+63.7% avg upside
18 analysts
$21.00
67.59% Upside
-22.9%
CLNN
Clene
Aug 15, 2023 BUY Strong Buy
+442.4% avg upside
11 analysts
$80.00
1231.06% Upside
-67.5%
TSE:CRDL
Cardiol Therapeutics
Aug 11, 2023 BUY Strong Buy
+636.1% avg upside
6 analysts
$4.24
182.84% Upside
·
ATAI
Atai Beckley N.V.
Aug 08, 2023 BUY Strong Buy
+230.1% avg upside
16 analysts
$11.00
170.96% Upside
-25.1%
STOK
Stoke Therapeutics
Aug 07, 2023 BUY Strong Buy
+25.1% avg upside
18 analysts
$14.00
54.94% Downside
+134.4%
DFTX
Definium Therapeutics
Aug 04, 2023 BUY Strong Buy
+44.9% avg upside
20 analysts
$7.00
71.33% Downside
+86.4%
FENC
Fennec Pharmaceuticals
Aug 03, 2023 BUY Strong Buy
+78.1% avg upside
9 analysts
$16.00
76.53% Upside
-28.1%
BHVN
Biohaven Ltd.
Aug 01, 2023 BUY Strong Buy
+87.5% avg upside
25 analysts
$31.00
128.35% Upside
+94.0%
NBIX
Neurocrine
Aug 01, 2023 BUY Strong Buy
+7.8% avg upside
37 analysts
$135.00
14.72% Downside
+48.1%
LUCD
Lucid Diagnostics
May 17, 2023 BUY Strong Buy
+350.9% avg upside
8 analysts
$4.00
270.45% Upside
-40.1%
ORMP
Oramed Pharm
Mar 24, 2023 HOLD Strong Buy
+396.3% avg upside
7 analysts
+35.4%
AVXL
Anavex Life Sciences
Dec 06, 2022 HOLD Strong Buy
+782.2% avg upside
9 analysts
$11.00
302.95% Upside
-4.4%
NVAX
Novavax
Jun 24, 2022 BUY Buy
+154.0% avg upside
20 analysts
$168.00
1740.14% Upside
-87.0%
INO
Inovio Pharmaceuticals
May 11, 2022 BUY Buy
+808.5% avg upside
19 analysts
$3.00
169.04% Upside
-56.9%
VTVT
vTv Therapeutics
Feb 18, 2022 BUY Strong Buy
-6.9% avg upside
12 analysts
$5.00
85.66% Downside
+1.3%
NEUP
Neuphoria Therapeutics
Jan 10, 2022 BUY Strong Buy
+365.8% avg upside
6 analysts
$52.00
1106.45% Upside
-61.6%
FLNA
Filana Therapeutics
Jul 15, 2021 HOLD Buy
+2987.5% avg upside
4 analysts
$100.00
8096.77% Upside
·
OVID
Ovid Therapeutics
Apr 19, 2021 HOLD Strong Buy
+108.4% avg upside
17 analysts
$4.00
76.21% Upside
-14.9%
VYGR
Voyager Therapeutics
Dec 23, 2020 HOLD Strong Buy
+284.7% avg upside
23 analysts
$10.00
168.80% Upside
-65.3%
GERN
Geron
May 31, 2020 BUY Strong Buy
+240.0% avg upside
19 analysts
$4.00
217.53% Upside
-14.8%
HALO
Halozyme
May 04, 2020 BUY Strong Buy
-13.7% avg upside
20 analysts
$39.00
43.05% Downside
+103.2%
TVRD
Tvardi Therapeutics
Apr 22, 2020 BUY Buy
+588.1% avg upside
23 analysts
$34.00
1192.76% Upside
+72.7%
CORT
Corcept Therapeutics
Feb 21, 2020 HOLD Buy
-45.6% avg upside
15 analysts
$15.00
81.18% Downside
+98.2%
ACET
Adicet Bio
Sep 09, 2019 BUY Strong Buy
+212.8% avg upside
14 analysts
$23.00
184.00% Upside
-78.9%
ECOR
Electrocore
May 30, 2019 HOLD Strong Buy
+537.6% avg upside
10 analysts
-52.3%
NTBLQ
Notable Labs
Mar 08, 2018 HOLD Buy
+809999900.0% avg upside
12 analysts
$4.00
399999900.02% Upside
·
SGMO
Sangamo Therapeutics
Feb 22, 2018 BUY Buy
+5843.7% avg upside
16 analysts
$32.00
18238.07% Upside
-65.2%
ALT
Altimmune
Oct 09, 2017 BUY Strong Buy
+935.8% avg upside
19 analysts
$180.00
6566.67% Upside
-94.0%
BCRX
BioCryst
Mar 16, 2017 BUY Strong Buy
+103.2% avg upside
24 analysts
$13.00
44.63% Upside
-39.0%
ARCT
Arcturus Therapeutics
Jan 17, 2017 HOLD Buy
+291.8% avg upside
35 analysts
$10.50
39.42% Upside
+45.3%
INCY
Incyte
Aug 01, 2016 BUY Buy
+1.0% avg upside
47 analysts
+43.1%
TRAW
Traws Pharma
Dec 08, 2015 BUY Buy
+3604.6% avg upside
10 analysts
$60.00
6956.38% Upside
-81.6%
PTN
Palatin Technologies
Aug 19, 2015 BUY Strong Buy
+899.8% avg upside
4 analysts
$4.00
65.78% Downside
-46.4%
TCRT
Alaunos Therapeutics
Mar 04, 2014 HOLD Buy
+603.1% avg upside
13 analysts
+199.8%
OSUR
Orasure Technologies
May 16, 2012 BUY Buy
+99.5% avg upside
11 analysts
$15.00
253.04% Upside
·
🔒 50 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Charles Duncan — Frequently Asked Questions
How accurate are Charles Duncan's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Charles's ratings were profitable over a one-year hold, with an average return of +13.8% per rating, or -5.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Charles ranked on 13Foresight?
Charles Duncan is currently ranked #2437 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on HRMY, SLDB, XENE, ALKS, ACAD, JAZZ, AXSM, VNDA, GHRS, DRUG, PRTA, VXRT and 43 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.